US Patent 9655945 Treatment of ascites
Patent 9655945 was granted and assigned to BioVie, Inc. on May, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 22 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+293 characters)
Article
Patent abstract
A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Jonathan Adams0
Paolo Angeli0
Penelope Markham0
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09655945 Treatment of ascites US Patent 9655945 Treatment of ascites
Infobox
Patent Number
096559450
Patent Number
96559450
Edits on 6 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
096559450
Date of Patent
May 23, 2017
0Patent Application Number
151980500
Date Filed
June 30, 2016
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 12 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 09655945 Treatment of ascites
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
09655945
Date of patent
May 23, 2017
Patent application number
15198050
Date Filed
June 30, 2016
Patent primary examiner
Find more entities like US Patent 9655945 Treatment of ascites
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
